Recommendation of the President – Tevimbra (tislelizumab)
On 9 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 141/2025 on the reimbursement of the medicinal product Tevimbra (tislelizumab) under the drug program: B.58. “Treatment of patients with esophageal, gastroesophageal junction, and gastric cancer (ICD-10: C15-C16)”